Skip to content

US · INMB · BIOTECHNOLOGY

INmune Bio, Inc. (INMB) intrinsic value and stock valuation

$0.83as of 2026-11-21 · Mkt cap 50.51M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

INmune Bio, Inc. DCF and intrinsic value

InvestorsCraft values INMB with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from INMB’s statements →

INmune Bio, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Boca Raton, FL 33432 inmunebio.com

How the business is doing

Fiscal 2015–2025, USD

Revenue
$50K+38% 5y CAGRd
20152025
Net income
-$-45.93M
20152025
Free cash flow
-$-23.62M
20152025
Total equity
$23.5M-9.5% 5y CAGRd
20152025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2015–2025, USD
20252024202320222021
Revenue$50K$10K$150K$370K$180K
Operating income-$-30.87M-$-42.63M-$-29.74M-$-25.95M-$-29.15M
Net income-$-45.93M-$-42.08M-$-30.01M-$-27.3M-$-30.34M
EPSd-$-1.73M-$-2.11M-$-1.67M-$-1.52M-$-1.88M
Operating cash flow-$-22.58M-$-33.36M-$-11.98M-$-22.69M-$-28.5M
Capital expenditure-$-1.04M$0.00$0.00$0.00-$-15M
Free cash flow-$-23.62M-$-33.36M-$-11.98M-$-22.69M-$-43.5M
Total assets$32.4M$39.6M$57M$81.8M$99.9M
Total debt$1.03M$380K$10.4M$15.3M$15.2M
Net debt-$-23.72M-$-20.54M-$-25.41M-$-36.84M-$-59.58M
Total equity$23.5M$32.1M$38.1M$60.1M$80.2M
Cash and short-term investments$24.8M$20.9M$35.9M$52.2M$74.8M
Income statement
20252024202320222021
Revenue$50K$10K$150K$370K$180K
Cost of revenue$0.00$0.00$0.00$0.00$0.00
Gross profit$50K$10K$150K$370K$180K
Research and development expenses$20.7M$33.2M$20.3M$17.1M$20.5M
Selling, general and administrative expenses$10.3M$9.48M$9.62M$9.26M$8.79M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$30.9M$42.7M$29.9M$26.3M$29.3M
Cost and expenses$30.9M$42.7M$29.9M$26.3M$29.3M
Interest income$850K$0.00$0.00$0.00$0.00
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$80K$550K$29.7M$26M$29.2M
Ebitda-$-45.85M-$-41.53M-$-270K-$-1.35M-$-1.19M
Operating income-$-30.87M-$-42.63M-$-29.74M-$-25.95M-$-29.15M
Total other income/expenses, net-$-15.06M$550K-$-270K-$-1.35M-$-1.19M
Income before tax-$-45.93M-$-42.08M-$-30.01M-$-27.3M-$-30.34M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-45.93M-$-42.08M-$-30.01M-$-27.3M-$-30.34M
Weighted average shares outstanding$26.6M$19.9M$18M$17.9M$16.1M
Weighted average diluted shares outstanding$26.6M$19.9M$18M$17.9M$16.1M
Balance sheet
20252024202320222021
Cash and short-term investments$24.8M$20.9M$35.9M$52.2M$74.8M
Net receivables$4.54M$1.41M$2.44M$8.46M$5.5M
Inventory$0.00$0.00$0.00$30K-$-5.5M
Total current assets$29.9M$22.7M$39.9M$64.7M$82.6M
Property, plant and equipment, net$910K$310K$410K$510K$730K
Goodwill and intangible assets$0.00$16.5M$16.5M$16.5M$16.5M
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$2.46M$16.9M$17.1M$17.1M$17.3M
Total assets$32.4M$39.6M$57M$81.8M$99.9M
Accounts payable$7.77M$6.56M$7.9M$5.21M$3.8M
Short-term debt$620K$140K$10M$5.09M$140K
Deferred revenue$0.00$0.00$0.00$620K$470K
Total current liabilities$8.42M$7.22M$18.5M$10.9M$4.36M
Long-term debt$410K$240K$400K$10.2M$15.2M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$410K$240K$400K$10.8M$15.4M
Capital lease obligations$1.03M$380K$520K$610K$780K
Total liabilities$8.83M$7.46M$18.9M$21.7M$19.7M
Common stock$30K$20K$820K$20K$20K
Retained earnings-$-209.04M-$-163.1M-$-121.02M-$-91.01M-$-63.72M
Accumulated other comprehensive income (loss)-$-740K-$-570K-$-800K-$-700K$0.00
Total equity$23.5M$32.1M$38.1M$60.1M$80.2M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$1.03M$380K$10.4M$15.3M$15.2M
Net debt-$-23.72M-$-20.54M-$-25.41M-$-36.84M-$-59.58M
Cash flow statement
20252024202320222021
Net income-$-45.93M-$-42.08M-$-30.01M-$-27.3M-$-30.34M
Depreciation and amortization$80K$0.00$0.00$0.00$0.00
Stock-based compensation$9.91M$7.61M$7.37M$7.15M$4.8M
Change in working capital-$-2.53M$1.04M$10.4M-$-2.86M-$-3.09M
Accounts receivable-$-3.13M$1.03M$6.02M-$-2.96M-$-3.71M
Inventory$0.00$0.00$0.00$2.96M$3.71M
Accounts payable$1.85M-$-1.37M$2.72M$1.4M$2.26M
Net cash provided by operating activities-$-22.58M-$-33.36M-$-11.98M-$-22.69M-$-28.5M
Investments in property, plant and equipment-$-1.04M$0.00$0.00$0.00-$-15M
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-1.04M$0.00$0.00$0.00-$-15M
Common stock issued$27.6M$27.8M$780K$700K$80.3M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$27.6M$18.2M-$-4.22M$730K$96.4M
Net change in cash$3.83M-$-14.93M-$-16.3M-$-22.66M$52.8M
Cash at end of period$24.8M$20.9M$35.9M$52.2M$74.8M
Operating cash flow-$-22.58M-$-33.36M-$-11.98M-$-22.69M-$-28.5M
Capital expenditure-$-1.04M$0.00$0.00$0.00-$-15M
Free cash flow-$-23.62M-$-33.36M-$-11.98M-$-22.69M-$-43.5M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About INmune Bio, Inc.

        INmune Bio, Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies. Its primary objective is to harness the body's innate immune system to combat various illnesses. The company is actively engaged in developing and bringing to market therapeutic candidates designed to address a spectrum of conditions such as blood cancers, solid tumors, and chronic inflammatory diseases. Its pipeline features key development programs including: INKmune: Aimed at treating women suffering from relapsed or refractory ovarian carcinoma and individuals diagnosed with high-risk myelodysplastic syndrome. INB03: An immunotherapy targeting patients with both hematologic malignancies and solid tumors. XPro1595: Under development for the treatment of Alzheimer's disease. INmune Bio holds licensing agreements with entities including Xencor, Inc., Immune Ventures, LLC, the University of Pittsburgh, and University College London. Established in 2015, INmune Bio is headquartered in Boca Raton, Florida.

        CEO
        David J. Moss
        Employees
        21
        Beta
        0.98

        Explore

        Frequently asked questions

        What is the intrinsic value of INmune Bio, Inc. (INMB)?

        InvestorsCraft does not currently publish an intrinsic value for INMB. How the IC value is calculated.

        Is INMB undervalued?

        InvestorsCraft does not publish an undervaluation signal for INMB at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.